People with multiple sclerosis (MS) face challenges adhering to disease-modifying drug
(DMD) treatment. Poor adherence to treatment reduces its clinical effectiveness which can …

Multiple sclerosis (MS) is a chronic, autoimmune, demyelinating disease of the central
nervous system (CNS). MS is an incurable disease. The goal of disease-modifying therapies …

Background Adherence to disease-modifying therapies (DMTs) is essential for the reduction
of multiple sclerosis (MS) progression and relapse. However, only limited data currently exist …

Purpose To evaluate adherence to disease-modifying therapies (DMTs) among patients with
multiple sclerosis (MS) initiating oral and injectable DMTs, and to estimate the impact of …

Adequate medication adherence is key for optimal benefit of pharmacological treatments. A
wealth of research has been conducted to understand and identify opportunities to intervene …

The treatment landscape for relapsing forms of multiple sclerosis (RMS) has expanded
considerably over the last 10 years with the approval of multiple new disease-modifying …

Objective Depression is common in multiple sclerosis (MS), but its impact on disability
worsening has not yet been determined. We explored the risk of disability worsening …

Background MS imposes a significant burden on patients, caregivers, employers, and the
healthcare system. Objective To comprehensively evaluate the US MS burden using …

Background Nonadherence to disease-modifying drugs (DMDs) for multiple sclerosis (MS)
is associated with poorer clinical outcomes, including higher rates of relapse and disease …

Multiple sclerosis (MS) is a disabling, chronic disease that imposes a significant economic
burden on patients and the US healthcare system. The largest cost component for …